Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting

Journal of Clinical Gastroenterology

Volumn 36, Issue 5, 2003, Pages 390-395

  Mardini, Houssam E ^a   Arnold, George L ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

6 Methylmercaptopurine (6 MMP); 6 Thioguanine nucleotides (6 TGNs); Azathioprine and 6 mercaptopurine (6 MP) metabolites; Immunomodulators; Inflammatory bowel disease; Pharmacogenetics

Indexed keywords

6 METHYLTHIOINOSINE; MERCAPTOPURINE; STEROID; THIOGUANOSINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG DEPENDENCE; ENTERITIS; FEMALE; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MEDICAL RECORD; OUTPATIENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; REMISSION; STEROID THERAPY;

6-MERCAPTOPURINE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIONUCLEOTIDES;

EID: 0037404458     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200305000-00005     Document Type: Article

References (35)

1. Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2000;2:446-50.
2. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:297-321.
3. Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory disease: a review of their mechanisms of efficacy and place in therapy. Drugs 1989;38: 267-88.
4. Hanauer SB. Drug therapy: inflammatory bowel disease. N Engl J Med 1996;334:841-8.
5. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3.
6. Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-8.
7. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
8. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101:39-46.
9. Dubinsky MC, Lamothe S, Yang, HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
10. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980;28:356-67.
11. Van EC, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63-8.
12. Lennard L, Van Loon J, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
13. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
14. Bouchnik Y, Lémann M, Mary J-Y, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347: 215-9.
15. Markowitz J, Grancher K, Mandel F, et al. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993;88:44-8.
16. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
17. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
18. Cuffari C, Theoret Y, Latour S. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
19. Stein RB, Lichtenstein GR. Medical therapy for Crohn's disease: the state of the art. Surg Clin North Am 2001;81:71-101.
20. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999;47:131-43.
21. Chan GL, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358-63.
22. Lennard L. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998;20:527-31.
23. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49:656-64.
24. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Pharmacol 1995;39:456-9.
25. Lewis. LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
26. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared with 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000;14:1009-14.
27. Kjeldsen J. Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol 1993;28:1-9.
28. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
29. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
30. Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000;68:210-9.
31. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
32. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-15.
33. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71-6.
34. Sebbag L, Boucher P, Davelu P, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine induced myelosuppression in heart transplant recipients. Transplantation 2000;69:1524-7.
35. Garza A, Sninsky CA. Change in red cell mean corpuscular volume (MCV) during azathioprine or 6-MP therapy for Crohn's disease may indicate optimal dose titration [abstract]. Gastroenterology 2001;A-624:3166.